<\/b><\/p>\n
<\/b><\/p>\n
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.<\/p>\n
Hospital Admissions Not Related to COVID-19 Fell in Early 2020<\/font><\/p>\n WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Non-COVID-19 hospital admissions decreased considerably with the onset of COVID-19, with declines generally similar across patient demographic subgroups from February to April 2020, according to a report published online Sept. 24 in Health Affairs<\/i>.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Cancer Mortality Higher for U.S. Counties With Persistent Poverty<\/font><\/p>\n WEDNESDAY, Sept. 30, 2020 (HealthDay News) — U.S. counties with persistent poverty (\u226520 percent of residents in poverty since 1980) have higher rates of cancer mortality, according to a study published online Sept. 30 in Cancer Epidemiology, Biomarkers & Prevention<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Private Health Plans Pay Hospitals 247 Percent of Medicare<\/font><\/p>\n MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.<\/p>\n More Information<\/a><\/p>\n Oral Steroids May Raise Risks for Diabetes, HTN, VTE in Children<\/font><\/p>\n WEDNESDAY, Sept. 23, 2020 (HealthDay News) — Children with current glucocorticoid exposure have increased risks for diabetes mellitus, hypertension, and venous thromboembolism (VTE), according to a study published online Sept. 9 in the American Journal of Epidemiology<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Impact of Psoriasis Explored for Hospital Outcomes of Acute MI<\/font><\/p>\n MONDAY, Sept. 21, 2020 (HealthDay News) — Myocardial infarction (MI) events may occur earlier in life in patients with psoriasis, which in turn may affect hospital outcomes, according to a study published online Sept. 11 in the Journal of the American Heart Association<\/i>.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Depression Common Among Psoriasis Patients<\/font><\/p>\n FRIDAY, Sept. 18, 2020 (HealthDay News) — Depression is common among patients with psoriasis, according to a study published online Sept. 14 in Dermatology<\/i>.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Cancer Incidence Up for Adolescents and Young Adults<\/font><\/p>\n THURSDAY, Sept. 17, 2020 (HealthDay News) — Among adolescents and young adults (AYAs), cancer incidence increased during 2007 to 2016, according to a report published online Sept. 17 in CA: A Cancer Journal for Clinicians<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Spironolactone Not Tied to Breast Cancer Recurrence<\/font><\/p>\n WEDNESDAY, Sept. 16, 2020 (HealthDay News) — Spironolactone is not independently associated with increased breast cancer recurrence, according to a study published in the October issue of the Journal of the American Academy of Dermatology<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Lipid-Rich Necrotic Core Linked to Psoriasis Severity<\/font><\/p>\n TUESDAY, Sept. 15, 2020 (HealthDay News) — For patients with psoriasis, lipid-rich necrotic core (LRNC) is associated with psoriasis severity and cardiovascular risk factors and is reduced for those patients receiving biologic therapy, according to a study published online Sept. 15 in Circulation: Cardiovascular Imaging<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n Widespread Avoidance of Medical Care Found Due to COVID-19 Concerns<\/font><\/p>\n THURSDAY, Sept. 10, 2020 (HealthDay News) — There was widespread reporting of avoidance of medical care due to COVID-19-related concerns in June 2020, according to research published in the Sept. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report<\/i>.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Shift Seen to Newer Agents to Treat Psoriasis<\/font><\/p>\n THURSDAY, Sept. 10, 2020 (HealthDay News) — Phototherapy use for psoriasis decreased from 2005 to 2018, while use of biologics increased, according to a research letter published online Sept. 4 in Dermatologic Therapy<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Permanent Hair Dye Not Linked to Cancer Risk, Mortality<\/font><\/p>\n TUESDAY, Sept. 8, 2020 (HealthDay News) — Use of permanent hair dye is not associated with the risk for most cancers or cancer mortality, according to a study published online Sept. 2 in The BMJ<\/i>.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Some Lupus Erythematosus Cases Tied to Drug Exposure<\/font><\/p>\n FRIDAY, Sept. 4, 2020 (HealthDay News) — Some cases of subacute cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) are drug-induced, according to a study published online Sept. 2 in JAMA Dermatology<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Benefit of Adjuvant Dabrafenib + Trametinib Persists in Melanoma<\/font><\/p>\n FRIDAY, Sept. 4, 2020 (HealthDay News) — For patients with stage III melanoma with BRAF<\/i> V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according to a study published online Sept. 2 in the New England Journal of Medicine<\/i>.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n